Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma.
Saved in:
| Title: | Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma. |
|---|---|
| Authors: | Stitzlein LM; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston., Nam D; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston., Hernandez FA; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston., Patel KH; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston., Poche A; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston., Ma H; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston., Impelman K; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston., Gumin J; Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston., Wang H; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston., Wang J; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston., Gadd S; Department of Pathology, Northwestern University, Chicago., Zaky W; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston.; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston., Becher O; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York., Dudley RW; Department of Pharmaceutical Sciences, College of Pharmacy, University of Findlay, Findlay., Lang FF; Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston., Sareddy GR; Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio.; Mays Cancer Center, University of Texas Health San Antonio, San Antonio., Chandra J; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston.; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2025 Nov 20; Vol. 7 (1), pp. vdaf246. Date of Electronic Publication: 2025 Nov 20 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
